167 related articles for article (PubMed ID: 17909066)
1. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
Wittmann BM; Sherk A; McDonnell DP
Cancer Res; 2007 Oct; 67(19):9549-60. PubMed ID: 17909066
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
3. Characterization of molecular and structural determinants of selective estrogen receptor downregulators.
Fan M; Rickert EL; Chen L; Aftab SA; Nephew KP; Weatherman RV
Breast Cancer Res Treat; 2007 May; 103(1):37-44. PubMed ID: 17033922
[TBL] [Abstract][Full Text] [Related]
4. Comparative analyses of mechanistic differences among antiestrogens.
Wijayaratne AL; Nagel SC; Paige LA; Christensen DJ; Norris JD; Fowlkes DM; McDonnell DP
Endocrinology; 1999 Dec; 140(12):5828-40. PubMed ID: 10579349
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for an unexpected mode of SERM-mediated ER antagonism.
Wu YL; Yang X; Ren Z; McDonnell DP; Norris JD; Willson TM; Greene GL
Mol Cell; 2005 May; 18(4):413-24. PubMed ID: 15893725
[TBL] [Abstract][Full Text] [Related]
6. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.
Connor CE; Norris JD; Broadwater G; Willson TM; Gottardis MM; Dewhirst MW; McDonnell DP
Cancer Res; 2001 Apr; 61(7):2917-22. PubMed ID: 11306468
[TBL] [Abstract][Full Text] [Related]
7. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
Wang L; Sharma A
ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12.
Lupien M; Jeyakumar M; Hébert E; Hilmi K; Cotnoir-White D; Loch C; Auger A; Dayan G; Pinard GA; Wurtz JM; Moras D; Katzenellenbogen J; Mader S
Mol Endocrinol; 2007 Apr; 21(4):797-816. PubMed ID: 17299137
[TBL] [Abstract][Full Text] [Related]
9. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
Wardell SE; Marks JR; McDonnell DP
Biochem Pharmacol; 2011 Jul; 82(2):122-30. PubMed ID: 21501600
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
11. Proteasome-independent down-regulation of estrogen receptor-alpha (ERalpha) in breast cancer cells treated with 4,4'-dihydroxy-trans-stilbene.
Balan KV; Wang Y; Chen SW; Chen JC; Zheng LF; Yang L; Liu ZL; Pantazis P; Wyche JH; Han Z
Biochem Pharmacol; 2006 Aug; 72(5):573-81. PubMed ID: 16822479
[TBL] [Abstract][Full Text] [Related]
12. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
14. Role of SUMOylation in full antiestrogenicity.
Hilmi K; Hussein N; Mendoza-Sanchez R; El-Ezzy M; Ismail H; Durette C; Bail M; Rozendaal MJ; Bouvier M; Thibault P; Gleason JL; Mader S
Mol Cell Biol; 2012 Oct; 32(19):3823-37. PubMed ID: 22826433
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
[TBL] [Abstract][Full Text] [Related]
16. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluorination on the pharmacological profile of 11beta isomers of fulvestrant in breast carcinoma cells.
Agouridas V; Magnier E; Blazejewski JC; Laïos I; Cleeren A; Nonclercq D; Laurent G; Leclercq G
J Med Chem; 2009 Feb; 52(3):883-7. PubMed ID: 19133777
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
19. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Vallet A; El Ezzy M; Diennet M; Haidar S; Bouvier M; Mader S
J Biol Chem; 2023 Jan; 299(1):102757. PubMed ID: 36460099
[TBL] [Abstract][Full Text] [Related]
20. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
